{"id":"olanzapine-and-amisulpride","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Metabolic syndrome"},{"rate":null,"effect":"Prolactin elevation"}]},"_chembl":{"chemblId":"CHEMBL243712","moleculeType":"Small molecule","molecularWeight":"369.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine is a thienobenzodiazepine that antagonizes dopamine D2 and serotonin 5-HT2A receptors, while amisulpride is a benzamide that selectively blocks dopamine D2/D3 receptors, particularly at mesolimbic and mesocortical pathways. Together, they provide complementary antipsychotic and mood-stabilizing effects through overlapping but distinct receptor profiles.","oneSentence":"This is a combination of two atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:04.784Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"}]},"trialDetails":[{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT04876521","phase":"PHASE4","title":"Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2019-10-14","conditions":"Post-Schizophrenic Depression","enrollment":60},{"nctId":"NCT04218981","phase":"NA","title":"Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders","status":"COMPLETED","sponsor":"Central South University","startDate":"2020-01-15","conditions":"Common Mental Disorder","enrollment":200},{"nctId":"NCT04529226","phase":"PHASE2","title":"Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-26","conditions":"Psychosis, Intellectual Disability","enrollment":75},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT04341467","phase":"NA","title":"Amisulpride Treatment for BPSD in AD Patients","status":"UNKNOWN","sponsor":"Tianjin Anding Hospital","startDate":"2019-12-01","conditions":"BPSD, Amisulpride, Olanzapine","enrollment":76},{"nctId":"NCT04002258","phase":"","title":"Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-06-06","conditions":"Schizophrenia, Antipyretics Toxicity, Prolactin Excess","enrollment":10363},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT01609153","phase":"PHASE4","title":"Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2012-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":328},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT01248195","phase":"PHASE4","title":"Optimization of Treatment and Management of Schizophrenia in Europe","status":"COMPLETED","sponsor":"Rene Kahn","startDate":"2011-05","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":479},{"nctId":"NCT02051387","phase":"PHASE1","title":"Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT01160991","phase":"NA","title":"Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2004-05","conditions":"Schizophrenia, Diabetes, Insulin Resistance","enrollment":10},{"nctId":"NCT00304616","phase":"PHASE4","title":"SWitching to Abilify Trial (SWAT)","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2004-10","conditions":"Schizophrenia","enrollment":500},{"nctId":"NCT00926965","phase":"PHASE4","title":"Tardive Dyskinesia and Cognitive Function","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2003-01","conditions":"Tardive Dyskinesia, Neurocognitive Function","enrollment":80},{"nctId":"NCT00419653","phase":"PHASE4","title":"Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy","status":"TERMINATED","sponsor":"University of Jena","startDate":"2003-01","conditions":"Schizophrenia","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":535,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zyprexa, Amisuprid Hexal"],"phase":"marketed","status":"active","brandName":"Olanzapine and Amisulpride","genericName":"Olanzapine and Amisulpride","companyName":"Heinrich-Heine University, Duesseldorf","companyId":"heinrich-heine-university-duesseldorf","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}